NCT05633602 2026-04-17
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
Phase 3 Active not recruiting
SWOG Cancer Research Network
Bristol-Myers Squibb
National Cancer Institute (NCI)
SWOG Cancer Research Network
Northwestern University
Eastern Cooperative Oncology Group
Bristol-Myers Squibb